Noted pediatric heart surgeon Dr. Kristine Guleserian has opened up her OR, and her career to author Mark Oristano to create Surgeon’s Story Inside OR 6 With a top Pediatric Heart Surgeon. Dr. Guleserian’s life, training and work are discussed in detail, framed around the incredibly dramatic story of a heart transplant operation for a two-year old girl whose own heart was rapidly dying. Find out more at- http://surgeonsstory.com/ Media Contact: For a review copy of Surgeon’s Story or to schedule an interviewwith Mark Oristano, contact Scott Lorenz of Westwind Communications Book Marketing, 734 667 2090 scottlorenz@westwindcos.com or http://www.book-marketing-expert.com Medical Non-Fiction
Former University of Texas great Colt McCoy is teaming up with Scott & White Healthcare as part of a philanthropic initiative to raise $50 million for a planned regional children’s hospital. The collaboration was announced today at a reception for hospital officials and donors at Scott & White Hospital in Temple.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sw/45124/
With Arizona facing its share of tragedies lately – economically, politically and most recently the wildfires which have impacted thousands of residents – the community has found comfort in rallying together to celebrate the grand opening of the new Phoenix Children’s Hospital. The campus of Arizona’s only hospital 100 percent for children grew from 345 licensed beds to 465, and will ultimately house 626 licensed beds at full build-out, expected in 2013.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phoenixchildrenshospital/50358/
Cancer is the leading cause of death by disease in children from ages 1 to 19 in the U.S. Yet, childhood cancer research and services are vastly and consistently underfunded. This weekend, Northwestern Mutual financial professionals and employees will support the fight against childhood cancer through its nonprofit partner, Alex’s Lemonade Stand Foundation (ALSF), by holding nearly 200 lemonade stands as part of the Foundation’s national fundraising initiative, Alex’s Lemonade Days (June 12-14).
Founded by Alex Scott (1996-2004) in 2004, Alex’s Lemonade Days is a three-day national event that grew out of Alex’s front yard lemonade stand. During Alex’s Lemonade Days, dedicated volunteers host thousands of Alex’s Lemonade Stands across the country, raising more than $1 million for childhood cancer research. June 2015 will mark the 12th Annual Lemonade Days, and will continue Alex’s mission to raise money one cup of lemonade at a time, renewing her idea that any contributor, at any age, can make a difference.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7422153-northwestern-mutual-lemonade-days/
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Nestlé Health Science will unveil its pediatric closed system formulas with the new SpikeRight® PLUS port at the annual American Society for Parenteral and Enteral Nutrition’s (A.S.P.E.N.) Clinical Nutrition Week meeting being held in Orlando January 21-24. The introduction marks a significant step in supporting the provision of safe enteral (tube) feeding.
Enteral tubing misconnections, where feeding solutions are wrongly administered through intravenous (IV) tubing or other non-enteral systems, have been a concern for nearly thirty years. Most commonly occurring in intensive care settings, where patients have multiple types of tubing connections, an enteral tubing misconnection can result in catastrophic complications and possibly death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53580-nestle-health-science-launches-next-generation-spikeright-plus-pediatrics
Today the International OCD Foundation (IOCDF), announced their support for children and families suffering from Sudden Onset Obsessive Compulsive Disorder. They are releasing two new PSAs created to bring awareness and engender change surrounding the disorder PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) and PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome).
To view Multimedia News Release, go to http://www.multivu.com/mnr/54781-ocd-foundation-pandas-psa-obsessive-compulsive-disorder
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Aflac, the number one provider of supplemental insurance in the United States, and recognized six times by Ethisphere as one of the World’s Most Ethical Companies, is once again teaming with Macy’s to produce and sell the 2012 Aflac Holiday duck . This is the twelfth year that Aflac and Macy’s are selling the annual plush duck, with all net proceeds going to support research and treatment for childhood cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58454-aflac-macys-annual-holiday-duck-design-pediatric-cancer-patient-atlanta
The St. Baldrick’s Foundation, a volunteer-powered charity dedicated to funding childhood cancer research, announces its Kids Are Special: Let’s Treat Them That Way national campaign. Focused on celebrating kids and giving them the happy childhoods they deserve, the campaign highlights the need for finding treatments that are specifically designed for kids with cancer.
With this bold new initiative, St. Baldrick’s looks to change the narrative around pediatric cancers, by showing kids as their truest selves – fun-loving, carefree, refreshingly honest, and always a little goofy. St. Baldrick’s puts the emphasis back on kids, while disempowering the label of “cancer.” All communication is strategically designed to remind us all that as adults we have the power to give kids happy childhoods free from cancer by helping to fund the best research worldwide. The campaign includes TV, print, radio, digital, and billboard placements featuring real kids doing kid-like things; from playing with their food to getting caught with paint on their faces, all with the message: Kids Are Special: Let’s Treat Them That Way.
To view the multimedia release go to:
http://www.multivu.com/players/English/7610752-st-baldricks-kids-are-special/
